Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
AFF3
REST API REST API
Homo sapiens
AFF3 is differentially expressed in 288 experiments: 128 organism parts: skeletal muscle, bone marrow, ... (126 more);, 161 disease states: normal, breast carcinoma, ... (159 more);, 96 cell types 386 cell lines 33 compound treatments and 80 other conditions.
Synonyms LAF4, MLLT2-like
Orthologs F1M222_RAT (Rattus norvegicus)   ENSGALG00000016767 (Gallus gallus)   AFF3 (Bos taurus)   Aff3 (Rattus norvegicus)   Aff3 (Mus musculus)   ENSCING00000005955 (Ciona intestinalis)   AFF3 (Danio rerio)   ENSGALG00000022777 (Gallus gallus)   lilli (Drosophila melanogaster)   AFF3 (Xenopus laevis)   ENSCAFG00000023079 (Canis familiaris)   ENSCAFG00000002243 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, regulation of transcription, DNA-dependent, double-stranded DNA binding, nucleus, embryonic hindlimb morphogenesis, response to tumor necrosis factor
UniProt Accession C9J622, C9J847, C9JC67, C9JMS1, C9JUC4, C9JUY1, C9JZ66, P51826, E7EMX9, C9JXV5
InterPro Term TF_AF4/FMR2
Search EB-eye ENSG00000144218
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MTAB-24, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, ... (36 experiments)

Factor Value U/D Experiments
LNCaP
3
E-GEOD-14464, E-GEOD-14990, E-GEOD-762
MCF-7
3
E-GEOD-5823, E-GEOD-20081, E-GEOD-19639
PC3
3
E-GEOD-14464, E-GEOD-5258, E-MEXP-2034
MDA468
2
E-MEXP-440, E-MTAB-62
BT474
2
E-MTAB-37, E-MEXP-440
MOLT4
2
E-MTAB-37, E-MTAB-62
380 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-4219, ... (48 experiments)

Factor Value U/D Experiments
CD56+ NK cells
2
E-TABM-145, E-AFMX-5
monocyte
1
2
E-GEOD-11755, E-MEXP-2019, E-GEOD-7307
endothelial cell
1
2
E-GEOD-19240, E-GEOD-3920, E-GEOD-3998
human embryonic stem cell
1
2
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
CXCR5(hi)ICOS(hi) CD4 T cell
1
E-MEXP-750
CD4+ cell
1
E-GEOD-7307
90 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-16363, ... (56 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-GEOD-4290, E-MTAB-37, E-GEOD-4412
breast carcinoma
1
3
E-GEOD-7307, E-TABM-276, E-MTAB-37, E-GEOD-5823
gastric carcinoma
2
E-MTAB-37, E-GEOD-2685
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
colon carcinoma
2
E-MTAB-37, E-MTAB-62
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
155 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-15205, E-TABM-782, E-GEOD-5824, E-GEOD-7708, ... (23 experiments)

Factor Value U/D Experiments
none
2
7
E-GEOD-20719, E-TABM-868, E-MEXP-1958, E-TABM-782, E-GEOD-412, ... (9 experiments)
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
unknown
1
E-GEOD-7307
eicosapentaenoic acid
1
E-MEXP-1389
BCR/ABL1
1
E-GEOD-15811
dihydrotestoterone
1
E-GEOD-7708
27 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
LT6
1
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19246, E-GEOD-2034, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-TABM-147, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, ... (9 experiments)

Genotype
studied in E-TABM-763, E-GEOD-22056, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-MEXP-1446, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-20559, E-TABM-276

Individual
studied in E-TABM-325, E-TABM-740, E-GEOD-974, E-GEOD-1926, E-MEXP-2069, ... (29 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-980, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22229, E-GEOD-1309, E-GEOD-22152, E-GEOD-17636, E-MEXP-1403 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Pr ihc
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7540, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-1561, E-GEOD-6532, E-GEOD-4922 ... (5 experiments)

Processing time: 0.376 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM